151 related articles for article (PubMed ID: 36383456)
1. Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas.
Zhou Y; Cui Y; Zhang D; Tong A
J Clin Endocrinol Metab; 2023 Feb; 108(3):755-766. PubMed ID: 36383456
[TBL] [Abstract][Full Text] [Related]
2. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.
De Filpo G; Maggi M; Mannelli M; Canu L
J Endocrinol Invest; 2021 Jan; 44(1):15-25. PubMed ID: 32602077
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapies in Pheochromocytoma and Paraganglioma.
Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
[TBL] [Abstract][Full Text] [Related]
4. Metastatic pheochromocytomas and paragangliomas: where are we?
Prinzi N; Corti F; Torchio M; Niger M; Antista M; Pagani F; Beninato T; Pulice I; Rossi RE; Coppa J; Cascella T; Giacomelli L; Di Bartolomeo M; Milione M; de Braud F; Pusceddu S
Tumori; 2022 Dec; 108(6):526-540. PubMed ID: 35593402
[TBL] [Abstract][Full Text] [Related]
5. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis.
Su D; Yang H; Qiu C; Chen Y
Front Oncol; 2023; 13():1141648. PubMed ID: 37483516
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
10. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapies for pheochromocytoma and paraganglioma.
Jimenez C; Fazeli S; Román-Gonzalez A
Endocr Relat Cancer; 2020 Jul; 27(7):R239-R254. PubMed ID: 32369773
[TBL] [Abstract][Full Text] [Related]
12. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
Wang K; Schütze I; Gulde S; Bechmann N; Richter S; Helm J; Lauseker M; Maurer J; Reul A; Spoettl G; Klink B; William D; Knösel T; Friemel J; Bihl M; Weber A; Fankhauser M; Schober L; Vetter D; Broglie Däppen M; Ziegler CG; Ullrich M; Pietzsch J; Bornstein SR; Lottspeich C; Kroiss M; Fassnacht M; Wenter VUJ; Ladurner R; Hantel C; Reincke M; Eisenhofer G; Grossman AB; Pacak K; Beuschlein F; Auernhammer CJ; Pellegata NS; Nölting S
Endocr Relat Cancer; 2022 May; 29(6):285-306. PubMed ID: 35324454
[TBL] [Abstract][Full Text] [Related]
13. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.
Pamporaki C; Prodanov T; Meuter L; Berends AMA; Bechmann N; Constantinescu G; Beuschlein F; Remde H; Januszewicz A; Kerstens MN; Timmers HJLM; Taïeb D; Robledo M; Lenders JWM; Pacak K; Eisenhofer G
Eur J Cancer; 2022 Jul; 169():32-41. PubMed ID: 35500459
[TBL] [Abstract][Full Text] [Related]
14. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
15. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.
Ye L; Santarpia L; Gagel RF
Endocr Rev; 2010 Aug; 31(4):578-99. PubMed ID: 20605972
[TBL] [Abstract][Full Text] [Related]
16. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service.
Kim JH; Moon H; Noh J; Lee J; Kim SG
Endocrinol Metab (Seoul); 2020 Mar; 35(1):157-164. PubMed ID: 32207276
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
Toledo R; Jimenez C
F1000Res; 2018; 7():. PubMed ID: 30109021
[TBL] [Abstract][Full Text] [Related]
20. New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach.
Jimenez C; Xu G; Varghese J; Graham PH; Campbell MT; Lu Y
Curr Oncol Rep; 2022 Jan; 24(1):89-98. PubMed ID: 35061191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
